Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Ep. 11: Factors in Selecting Therapy for mCRPC

March 31st 2020

Ep. 10: How Has the mCRPC Treatment Landscape Changed?

March 31st 2020

Ep. 9: Neurological AEs and Quality of Life in Treating nmCRPC

March 31st 2020

Ep. 8: Selecting Optimal AR-Targeted Therapy for nmCRPC

March 31st 2020

Ep. 7: Current Treatment and Imaging Options for nmCRPC

March 31st 2020

Ep. 6: Identifying Nonmetastatic CRPC

March 31st 2020

Ep. 5: Ongoing CSPC Clinical Trials

March 31st 2020

Ep. 4: Currently Approved Therapies for Metastatic CSPC

March 31st 2020

Ep. 3: Addressing Cardiovascular Risk and Events in CSPC

March 31st 2020

Ep. 2: Identifying and Monitoring Testosterone Levels in CSPC

March 31st 2020

Ep. 1: Initiating Therapy for CSPC

March 31st 2020

Dr. Oh on Results From the PRINT Trial in mCRPC

March 31st 2020

William K. Oh, MD, sheds light on the results of the phase II PRINT trial in metastatic castration-resistant prostate cancer.

Dr. Sartor on Implications of PSMA-PET Positivity in Prostate Cancer

March 31st 2020

A. Oliver Sartor, MD, discusses the implications of prostate-specific membrane antigen-PET positivity in prostate cancer.

Dr. Antonarakis on the Utility of Sipuleucel-T Plus Radium-223 in Nonmetastatic CRPC

March 31st 2020

Emmanuel S. Antonarakis, MBBCh, discusses the utility of sipuleucel-T plus radium-223 in nonmetastatic castration-resistant prostate cancer.

Dr. Agarwal on the Safety of Cabozantinib/Atezolizumab in mCRPC

March 31st 2020

Neeraj Agarwal, MD, discusses the safety profile ofcabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Darolutamide Approved in Europe for Nonmetastatic CRPC

March 30th 2020

The European Commission has approved darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer who are at high risk for developing metastatic disease.

Familial History of Prostate Cancer Strongly Linked With Early-Onset Disease

March 30th 2020

While the risk of prostate cancer varies by family history, it is strongly associated with early onset of disease.

Dr. de Wit on the AEs With Cabazitaxel in the CARD Trial in mCRPC

March 28th 2020

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the adverse events (AEs) with cabazitaxel (Jevtana) in the phase III CARD trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Hussain on the Implications of the PROfound Trial in mCRPC

March 28th 2020

Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center, of Northwestern University Feinberg School of Medicine, discusses the implications of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Parker on the Results of the RADICALS-RT Trial in Prostate Cancer

March 28th 2020

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the results of the phase III RADICALS-RT trial in prostate cancer.